Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Enlivex Therapeutics Ltd
(NQ:
ENLV
)
1.300
+0.050 (+4.00%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
25,699
Open
1.220
Bid (Size)
1.240 (20)
Ask (Size)
1.300 (2)
Prev. Close
1.250
Today's Range
1.210 - 1.300
52wk Range
1.150 - 4.590
Shares Outstanding
18,306,186
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
GreenPower and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money™ Show on Bloomberg TV
August 30, 2024
Via
ACCESSWIRE
Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
July 23, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Performance
YTD
-60.61%
-60.61%
1 Month
-2.26%
-2.26%
3 Month
-11.56%
-11.56%
6 Month
-61.99%
-61.99%
1 Year
-44.68%
-44.68%
More News
Read More
Enlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
July 19, 2024
Via
ACCESSWIRE
CEO Spotlight: Enlivex Therapeutics CEO Tells Why And How Recent Milestones Can Transform This MedTech Company ($ENLV)
July 17, 2024
Via
AB Newswire
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
June 24, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
June 20, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
June 17, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
June 03, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
May 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
May 28, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
April 29, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis
April 22, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis
April 16, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Tesla To $180? Here Are 10 Top Analyst Forecasts For Friday
April 12, 2024
Via
Benzinga
Nasdaq Jumps 250 Points; Crude Oil Down 1%
April 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
Fossil Fuels
US Equities
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Via
Benzinga
Dow Dips 100 Points; CarMax Earnings Miss Views
April 11, 2024
Via
Benzinga
Topics
Earnings
Stocks
Exposures
Financial
US Equities
Nasdaq Gains Over 50 Points; US Producer Prices Increase In March
April 11, 2024
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
April 11, 2024
From
Enlivex Therapeutics Ltd
Via
GlobeNewswire
ENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023
April 05, 2024
Via
InvestorPlace
Enlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
March 22, 2024
Via
ACCESSWIRE
Enlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee Osteoarthritis
February 26, 2024
Via
ACCESSWIRE
Enlivex Completes Enrollment Of All 120 Patients In Phase 2 Trial Of Allocetra In Patients With Sepsis, Third-Leading Cause Of Mortality In US Hospitals
February 21, 2024
Via
ACCESSWIRE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.